KAI-9531

Phase 3Small molecule

KKailera

KAI-9531 is one of 31 small molecule programs targeting Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

ObesityPhase 3

Active, not recruiting

Competition

Competitive Landscape

393 competitors in Obesity

#DrugCompanyPhaseTrials

KAI-9531

KKailera

Phase 3

2 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Amidate

Adenocard

Colcrys

Alnylam Pharmaceuticals

Activella

Calciferol

Alnylam Pharmaceuticals

Preclinical

—9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 10

Prometrium

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Obesity

NCT07458269

Q1 2028

Phase 3Recruiting

Overweight

NCT07284875

Q2 2028

Phase 3Recruiting

Obesity

NCT07284979

Phase 3Recruiting

Overweight

NCT07284901

Clinical

Trials by Indication[1]

Obesity2 trials

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Recruiting·KKailera·Phase 3·NCT07284979·1,200 enrolled

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Not yet recruiting·KKailera·Phase 2·NCT07458269·250 enrolled

Overweight2 trials

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Recruiting·KKailera·Phase 3·NCT07284901·1,700 enrolled

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Recruiting·KKailera·Phase 3·NCT07284875·1,800 enrolled

Unspecified1 trial

A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices

Completed·KKailera·Phase 1·NCT07044401·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for KAI-9531. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KAI-9531 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KAI-9531. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kailera company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKailera

KAI-9531

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Obesity2 trials

Overweight2 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News